英文字典,中文字典,查询,解释,review.php


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       


安装中文字典英文字典辞典工具!

安装中文字典英文字典辞典工具!










  • Stock Information | Insmed Incorporated
    Stock Information The interactive chart below shows a historical timeline of our stock price and trading volume Click on the tabs below to view the different timeframes You may also view data on Dividend, Split, and Earning History by using the Events tab
  • Insmed Incorporated Investor Relations
    Insmed (Nasdaq:INSM) is a people-first global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases Our strong and experienced management team embodies our culture, setting the tone for an organization that acts boldly, thinks creatively, and puts patients first in everything we do
  • Insmed | For us, everything starts with people.
    Get to know Insmed, see what drives us, and learn how we’re building a company where people come first Find available career opportunities in the U S , Japan, or Europe See how we collaborate with patients to shape every step of our shared journey Learn more about our clinical trials or find a relevant trial near you
  • Insmed Reports Third-Quarter 2025 Financial Results and Provides . . .
    Insmed anticipates commercial launches for the EU, UK, and Japan in 2026, pending approval in each territory Insmed expects to report topline data from the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) by early January 2026
  • News Releases | Insmed Incorporated
    Want to stay up to date on our news, events, and filings? Set up your email alerts
  • Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and . . .
    Insmed continues to anticipate full-year 2026 ARIKAYCE revenues in the range of $450 million to $470 million ARIKAYCE global revenue grew 19% in 2025 compared to 2024, reflecting year-over-year growth across all geographic regions and exceeding the upper end of 2025 guidance of $420 to $430 million
  • Insmed Reports Third-Quarter 2024 Financial Results and Provides . . .
    Insmed issued approximately 5 7 million shares of common stock in connection with the redemption and earlier conversions of notes (ii) The Company raised an additional $371 million in net proceeds under its at-the-market equity offering program during the third quarter, at an average sales price of $75 64 per share
  • Insmed Reports Second-Quarter 2025 Financial Results and Provides . . .
    In June 2025, Insmed completed a public offering of 8,984,375 shares of common stock, including 1,171,875 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares


















中文字典-英文字典  2005-2009